# Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

> **NCT02461771** · PHASE1 · COMPLETED · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** Pegcetacoplan

## Key facts

- **NCT ID:** NCT02461771
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-28
- **Primary completion:** 2016-03-08
- **Final completion:** 2016-03-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461771, "Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02461771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*